- Home
- CLST vs MRSN Comparison
CLST vs MRSN Comparison
Compare CLST & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLST
- MRSN
- Stock Information
- Founded
- CLST 1922
- MRSN 2001
- Country
- CLST United States
- MRSN United States
- Employees
- CLST N/A
- MRSN N/A
- Industry
- CLST
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CLST
- MRSN Health Care
- Exchange
- CLST Nasdaq
- MRSN Nasdaq
- Market Cap
- CLST 54.6M
- MRSN 47.1M
- IPO Year
- CLST N/A
- MRSN 2017
- Fundamental
- Price
- CLST $13.30
- MRSN $9.88
- Analyst Decision
- CLST
- MRSN Strong Buy
- Analyst Count
- CLST 0
- MRSN 3
- Target Price
- CLST N/A
- MRSN $33.00
- AVG Volume (30 Days)
- CLST 4.8K
- MRSN 69.7K
- Earning Date
- CLST 10-24-2025
- MRSN 11-12-2025
- Dividend Yield
- CLST N/A
- MRSN N/A
- EPS Growth
- CLST N/A
- MRSN N/A
- EPS
- CLST 0.58
- MRSN N/A
- Revenue
- CLST $11,354,000.00
- MRSN $34,769,000.00
- Revenue This Year
- CLST N/A
- MRSN N/A
- Revenue Next Year
- CLST N/A
- MRSN N/A
- P/E Ratio
- CLST $23.01
- MRSN N/A
- Revenue Growth
- CLST 164.54
- MRSN 16.14
- 52 Week Low
- CLST $10.67
- MRSN $5.21
- 52 Week High
- CLST $14.23
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- CLST 64.78
- MRSN 74.47
- Support Level
- CLST $13.20
- MRSN $7.83
- Resistance Level
- CLST $13.37
- MRSN $11.12
- Average True Range (ATR)
- CLST 0.05
- MRSN 0.75
- MACD
- CLST -0.01
- MRSN 0.18
- Stochastic Oscillator
- CLST 72.12
- MRSN 76.65
About CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.